



13 May 2021

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Medlab appoints Pharmaceutical executive as CFO & Company Secretary

Sydney, Australia; 13 May 2021: Medlab Clinical Limited (ASX:MDC) (**Medlab** or **Company**) an Australian biotech using delivery platforms to enhance medicines particularly in the field of oncology, today announces the appointment of Mr Kerem Kaya as Chief Financial Officer of Medlab.

Mr Kaya joins Medlab with extensive pharmaceutical industry and financial experience gained at one of the world's largest pharmaceutical companies, Novartis.

Mr Kaya has spent nearly 15 years at Novartis Pharmaceuticals working across several divisions, notably spending five years as Global Finance Projects Manager of Novartis AG where he helped develop financial efficiencies across the business globally. Mr Kaya was most recently Head of Finance Planning and Analysis for the Australian and New Zealand operations.

"I am delighted to welcome Mr Kaya as Chief Financial Officer of Medlab. He brings an exceptional combination of leadership combined with financial, strategic, and global experience in the pharmaceutical sector. We continue to build out a high calibre team, with global pharmaceutical industry experience, creating an organisational structure that will support our clinical and commercial expansion into the US and UK," said Dr Sean Hall, CEO & Managing Director of Medlab.

"I'd like to thank Mr Simon Allsop for his role as interim CFO while we undertook the recruitment process for Chief Financial Officer." Dr Hall said.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab – www.medlab.co

Medlab Clinical LTD (ASX:MDC) is pioneering the development and commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's pipeline comprises of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Medlab's Patented lead drug candidate, NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain.

NanaBis™, as it moves in global P3 trials is public facing on www.clinicaltrials.gov NCT04808531. NanoCelle©, the patented delivery platform is wholly owned by Medlab Clinical and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle© is designed to address known medication problems, addressing global unmet medical needs.

Medlab operates in Australia (Head Office), USA, and the UK.

Medlab – *better medicines, better patient care.*

For further information contact:

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 - sean_hall@medlab.co	Kyahn Williamson, WE Communications T: + 61 0401018828 - kwilliamson@we-worldwide.com
---	--